Last reviewed 2026-04-20 · How we verify

Ancyte (PIPOSULFAN)

Phase 2 active Small molecule

Ancyte (generic name: PIPOSULFAN) is a piposulfan drug. It is currently in Phase 2 development.

Ancyte works by inhibiting a specific enzyme or pathway, although the exact details of its mechanism are not well understood.

Ancyte, also known as piposulfan, is a small molecule drug of the piposulfan class. Its target and exact mechanism of action are unknown. It is not clear if Ancyte is FDA-approved or commercially available. Further information on its approved indications, half-life, bioavailability, generic manufacturers, and patent status is not available. As a result, its commercial status and key safety considerations cannot be determined.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PIPOSULFAN
Drug class	piposulfan
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Ancyte like a key that fits into a lock, but instead of unlocking a door, it blocks a specific process in the body. This process is controlled by an enzyme or a series of chemical reactions, and Ancyte's presence helps to slow it down or prevent it from happening. By doing so, Ancyte may help to treat certain conditions, but more research is needed to understand its effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ancyte CI brief — competitive landscape report
Ancyte updates RSS · CI watch RSS

Frequently asked questions about Ancyte

What is Ancyte?

Ancyte (PIPOSULFAN) is a piposulfan drug.

How does Ancyte work?

Ancyte works by inhibiting a specific enzyme or pathway, although the exact details of its mechanism are not well understood.

What is the generic name of Ancyte?

PIPOSULFAN is the generic (nonproprietary) name of Ancyte.

What drug class is Ancyte in?

Ancyte belongs to the piposulfan class. See all piposulfan drugs at /class/piposulfan.

What development phase is Ancyte in?

Ancyte is in Phase 2.

Drug class: All piposulfan drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing